ALNY - Alnylam preliminary FY22 net product revenues for 4 drugs rises 35% Y/Y

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) said preliminary full year global net product revenues for its drugs Onpattro, Amvuttra, Givlaari and Oxlumo amounted to $894M, growing +35% Y/Y (+43% Y/Y at constant exchange rate).

Onpattro (patisiran) and Amvuttra (vutrisiran) are part of the company's TTR Franchise: to treat polyneuropathy in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.

The company said preliminary global net product revenues for Onpattro and Amvuttra in Q4 were ~$122M and $69M, respectively. For the full year 2022 sales of Onpattro and Amvuttra  were ~$558M and $94M, respectively, representing 37% total TTR annual growth compared to full year 2021.

Preliminary Q4 global net net product revenues of Givlaari (givosiran) — which is used to treat adults with acute hepatic porphyria — were  $47M. For full year sales grew 35% Y/Y to $173M.

Oxlumo — which is  used for treating primary hyperoxaluria type 1 — saw preliminary global net product revenues of $24M in Q4. For fill year sales grew 17% Y/Y to $70M.

Alnylam said that as of Dec. 31, 2022 it had preliminary cash, cash equivalents, and marketable securities of ~$2.2B.

"We are pleased to have closed out 2022 on a very strong note with continued execution across our commercial portfolio, delivering top-line revenue in line with our guidance range," said Alnylam CEO Yvonne Greenstreet.

For further details see: